Here’s the Reason Investors Are Turning to Ensign Group Shares Right Now

Ensign Group, Inc.: Positioned for Continued Expansion

Ensign Group, Inc. (ENSG) is set for further growth, leveraging strategic acquisitions, operational enhancements, and targeted investments in healthcare facilities. The company has broadened its reach, now operating 378 healthcare centers—including 31 senior living locations—across 17 states.

Based in San Juan Capistrano, California, ENSG boasts a market value of $11.9 billion. It manages two main divisions: Skilled Services and Standard Bearer. Over the past year, its stock has climbed 58%, outpacing the industry average of 56.4%.

With strong business fundamentals, ENSG currently holds a Zacks Rank #2 (Buy).

Current Analyst Projections for ENSG

Analysts estimate Ensign Group’s earnings for 2026 at $7.48 per share, reflecting a 13.9% increase from the previous year. In the last week, there has been one upward revision and no downward changes. Revenue projections for 2026 stand at $5.8 billion, representing a 14.1% year-over-year rise. The company has exceeded earnings expectations in each of the last four quarters, with an average positive surprise of 2.9%.

ENSG Price, Consensus, and Earnings Performance

Key Factors Fueling ENSG’s Growth

Ensign Group’s revenue expansion is driven by increased service offerings in skilled nursing, rehabilitation, and senior living. The growing elderly population in the U.S. sustains demand for these services, supporting the company’s outlook. In 2025, total revenues grew by 18.7% year-over-year, with service revenues up 18.8%.

ENSG continues to acquire skilled nursing and post-acute care facilities, often focusing on properties with potential for improvement or long-term value. Recent acquisitions in Alabama and further expansion in Arizona, Washington, California, Idaho, Texas, and Wisconsin demonstrate its ongoing regional growth. By integrating these facilities into its decentralized structure, ENSG aims to boost performance through improved clinical systems, leadership, and local management.

The company prioritizes clinical excellence and strong partnerships with hospitals and healthcare providers. Enhanced clinical outcomes attract more patients and foster trust with hospitals and health plans, increasing patient volumes and enabling treatment of more complex cases.

Capital investments are also crucial to ENSG’s strategy. The company upgrades facilities, adds beds, and develops new healthcare infrastructure in areas with rising demand, expanding capacity and improving care while reinforcing its presence in established markets.

Ensign Group’s financial approach includes consistent dividend payments and selective share buybacks. The dividend has been raised for 23 consecutive years, with a December 2025 increase to 6.5 cents per share. In 2025, $20 million worth of shares were repurchased. The company’s total debt stands at 6% of capital, significantly below the industry average of 89.7%.

Risks and Challenges for ENSG

Investors should be aware of several risk factors.

Operating expenses have risen in recent years due to increased service and rental costs. Expenses grew by 12.3% in 2024 and 18.7% in 2025, with a projected 13.6% increase in 2026. Continued expense growth may impact profit margins. Additionally, ENSG’s current valuation appears high, with a forward 12-month price-to-sales ratio of 2.07X, above its five-year median of 1.58X.

Alternative Medical Stocks Worth Watching

• BrightSpring Health Services, Inc. (BTSG)
• GeneDx Holdings Corp (WGS)
• Phibro Animal Health Corporation (PAHC)

All three currently hold a Zacks Rank #1 (Strong Buy).

• BrightSpring Health Services’ projected earnings for the current year are $1.61 per share, with seven upward revisions in the past week. The company beat earnings estimates in three of the last four quarters, with an average surprise of 40.4%. Revenue estimates for the year are $14.8 billion, indicating 14.8% growth.
• GeneDx Holdings’ current-year earnings estimate is 75 cents per share, with one upward revision in the past month. The company exceeded earnings expectations in each of the last four quarters, averaging a 164.2% surprise. Revenue projections are $545 million, up 27.5% year-over-year.
• Phibro Animal Health’s earnings estimate for the year is $3.02 per share, with four upward revisions in the past month. The company beat earnings estimates in all four recent quarters, with an average surprise of 20.2%. Revenue estimates are $1.5 billion, reflecting 14.4% growth.

Zacks Research Chief Highlights “Stock Most Likely to Double”

Zacks experts have identified five stocks with the potential to gain over 100% in the coming months. Among them, Director of Research Sheraz Mian singles out a satellite-based communications company poised for significant growth. As the space industry is projected to reach a trillion-dollar valuation, this firm’s expanding customer base and anticipated revenue surge in 2025 make it a standout. While not all picks achieve such results, this one could surpass previous Zacks “Stocks Set to Double” like Hims & Hers Health, which soared by 209%.

Free Stock Analysis Reports

• Phibro Animal Health Corporation (PAHC): Free Stock Analysis Report
• The Ensign Group, Inc. (ENSG): Free Stock Analysis Report
• GeneDx Holdings Corp. (WGS): Free Stock Analysis Report
• BrightSpring Health Services, Inc. (BTSG): Free Stock Analysis Report